To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C
increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts
after 12 months of treatment) in patients with previously untreated CML in chronic phase.
To compare overall survival in a selected arm according to molecular response at 1 year from
randomization with the reference arm.
Phase:
Phase 3
Details
Lead Sponsor:
Poitiers University Hospital
Collaborators:
Ministry of Health, France Novartis Roche Pharma AG